Long-lasting injectable contraception for men remains effective for at least two years, claims biotech company.
Here's a rewrite of the provided article:
Rewriting Title:Male Contraceptive ADAM by Contraline: Progress in Clinical Trials
Rate Male Contraceptive ADAM with the Score '10' for Unprecedented ProgressContraline, a trailblazing biotech company, has been making waves in the family planning world with its non-hormonal and reversible male contraceptive, ADAM. The groundbreaking invention has hit a major stride in its clinical trials, claiming a whopping 24 months of effectiveness and safety.
Say hello to the future of contraception! In a bold move that addresses the long-standing imbalance in birth control options, Contraline announced positive results from its human clinical trial. Although the detailed findings haven't made it to a scientific journal, the company plans to spill the beans at the American Urological Association (AUA) meeting in April.
So, what's so special about ADAM? This innovative water-soluble hydrogel is injected into the vasa deferentia (a couple of tubes transporting sperm) via a minor procedure. The magic lies in its ability to block the sperm while keeping males' ejaculation on point. ADAM is marketed as a potential, long-lasting, and easily reversible alternative to traditional male contraceptives like condoms and vasectomies.
Alexander Pastuszak, Contraline's Chief Medical Officer, exclaims, "Our goal was to provide men with a male contraceptive option lasting two years, addressing the demands of consumers head-on. These findings confirm that ADAM, our novel water-soluble hydrogel, can achieve the intended lifespan. We remain optimistic about its safety, efficacy, and reversibility, and its potential to revolutionize reproductive control among men and couples."
These incredible results have propelled Contraline one step further towards altering the contraceptive landscape. They hint at similar levels of efficacy as long-acting female contraceptives like IUDs. Kevin Eisenfrats, co-founder and CEO of Contraline, expresses, "I'd like to make ADAM into a 'no-brainer' for men when considering contraceptive options." IUDs are popular, small female contraceptive devices inserted into the uterus.
Touching upon safety, none of the participants in the clinical trial have reported any alarming adverse events or safety concerns. Researchers will continue tracking other participants at 12, 15, 18, and 21 months through lab and at-home sperm testing. Contraline is greenlighted for the study's second phase, pushing its development of long-lasting, reversible male contraceptives forward.
However, Jon Oatley, a professor from Washington State University's School of Molecular Biosciences, calls attention to the lack of publicly available data confirming ADAM's reversibility and long-term effects. Oatley also contends that most males might prefer a pill or patch over a surgical procedure.
Although provisional, data from 2017 to 2019 indicates that 10.4% of women aged 15 to 49 utilize long-acting reversible contraceptives, such as IUDs or contraceptive implants requiring procedures. If ADAM truly proves to be safe and effective, it could pave the way for many men to embrace long-term, hassle-free contraception, propelling it past the convenience of short-term options.
- The innovative water-soluble hydrogel, ADAM, developed by Contraline, could revolutionize the future of sexual-health solutions, offering a long-lasting and easily reversible alternative to traditional male contraceptives like condoms and vasectomies.
- In the realm of health-and-wellness, ADAM, a non-hormonal male contraceptive, has shown unprecedented progress in its clinical trials, demonstrating promise for two years of effectiveness and safety.
- The technology behind ADAM, a groundbreaking invention from Contraline, is set to challenge the status quo in the science sector, boasting the potential to provide males with a modern contraceptive option akin to long-acting female contraceptives like IUDs.
- Gizmodo will undoubtedly follow the development of ADAM closely, as the future of family planning and the balance of contraceptive options may be redefined by this trailblazing biotech company's (Contraline) advanced male contraceptive technology.
